In addition, tumor heterogeneity may result in varied HHLA2 expression within different tumor regions, affecting interpretations, as observed for proteins of other immune checkpoint signaling pathways (Janakiram et al. 2015, Yang et al. 2022). This evidence concerns the gene HHLA2 and neoplasm.